Related references
Note: Only part of the references are listed.A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
Ye Zhu et al.
GENETICS IN MEDICINE (2021)
Impact of Previous Genetic Counseling and Objective Numeracy on Accurate Interpretation of a Pharmacogenetics Test Report
Kelly Drelles et al.
PUBLIC HEALTH GENOMICS (2021)
Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial
David W. Oslin et al.
CONTEMPORARY CLINICAL TRIALS (2021)
Expanding evidence leads to new pharmacogenomics payer coverage
Philip E. Empey et al.
GENETICS IN MEDICINE (2021)
Ending the pharmacogenomic gag rule: the imperative to report all results
Colin M. E. Halverson et al.
PHARMACOGENOMICS (2021)
Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
Tessa A. M. Mulder et al.
CANCERS (2021)
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy A Meta-Analysis
Naveen L. Pereira et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2021)
Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial
Andrea DeCensi et al.
NPJ BREAST CANCER (2021)
Implementation of a Pharmacogenomic Testing Service through Community Pharmacy in the Netherlands: Results from an Early Service Evaluation
Tracey Thornley et al.
PHARMACY (2021)
Hmong participants' reactions to return of individual and community pharmacogenetic research results: A positive light for our community
K. Holzer et al.
JOURNAL OF COMMUNITY GENETICS (2021)
Pragmatic Trials in Genomic Medicine: The Integrating Pharmacogenetics In Clinical Care (I-PICC) Study
Charles A. Brunette et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI Results of the GIANT Study
Jean-Sebastien Hulot et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Pharmacogenomic-Based Decision Support to Predict Adherence to Medications
Carlton Christian et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic
Meghan J. Arwood et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Patient insights on features of an effective pharmacogenomics patient portal
Tien M. Truong et al.
PHARMACOGENETICS AND GENOMICS (2020)
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial
Naveen L. Pereira et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major US sources
Tyler Shugg et al.
NPJ GENOMIC MEDICINE (2020)
Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?
Rachel Huddart et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Daniel M. F. Claassens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Implementation of wide-scale pharmacogenetic testing in primary care
Natasha Petry et al.
PHARMACOGENOMICS (2019)
Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update
Mary Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial
D. Max Smith et al.
GENETICS IN MEDICINE (2019)
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Matthew P. Goetz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome
Dan M. Roden et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Larisa H. Cavallari et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2018)
Patient perspectives following pharmacogenomics results disclosure in an integrated health system
Amy A. Lemke et al.
PHARMACOGENOMICS (2018)
Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward
Kelly E. Caudle et al.
PHARMACOGENOMICS (2018)
Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population
Yee Ming Lee et al.
PHARMACOTHERAPY (2018)
When will clinical trials finally reflect diversity?
Todd C. Knepper et al.
NATURE (2018)
Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations
Jasmine A. Luzum et al.
PHARMACOGENOMICS (2018)
Physician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey
Aniwaa Owusu Obeng et al.
JOURNAL OF PERSONALIZED MEDICINE (2018)
Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?
S. J. Bielinski et al.
PHARMACOGENOMICS JOURNAL (2017)
Clinical pharmacogenomics: patient perspectives of pharmacogenomic testing and the incidence of actionable test results in a chronic disease cohort
Chandrama Mukherjee et al.
PERSONALIZED MEDICINE (2017)
Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now
Kristin W. Weitzel et al.
PHARMACEUTICAL RESEARCH (2017)
Clinical Trial Designs to Support Clinical Utility of Pharmacogenomic Testing
Katarzyna Drozda et al.
PHARMACOTHERAPY (2017)
Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs
Michael B. Bottorff et al.
PHARMACOTHERAPY (2017)
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems
J. A. Luzum et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
Win-Kuang Shen et al.
CIRCULATION (2017)
Discerning the clinical relevance of biomarkers in early stage breast cancer
Tarah J. Ballinger et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting
L. H. Cavallari et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium
C. H. van der Wouden et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Evidence and resources to implement pharmacogenetic knowledge for precision medicine
Kelly E. Caudle et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2016)
A brighter future for the implementation of pharmacogenomic testing
Cathelijne H. van der Wouden et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2016)
Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Lyndsay N. Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes A GeT-RM Collaborative Project
Victoria M. Pratt et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services
J. Kevin Hicks et al.
PHARMACOTHERAPY (2016)
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands
B. A. L. M. Deiman et al.
NETHERLANDS HEART JOURNAL (2016)
Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers
Henry M. Dunnenberger et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55 (2015)
Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies
Julie A. Johnson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Pharmacogenomics in the clinic
Mary V. Relling et al.
NATURE (2015)
Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies
Julie A. Johnson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Clinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic Testing
S. L. Van Driest et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Meaningful Use of Pharmacogenetics
M. J. Ratain et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Useless Until Proven Effective: The Clinical Utility of Preemptive Pharmacogenetic Testing
A. C. J. W. Janssens et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Evidence Required to Demonstrate Clinical Utility of Pharmacogenetic Testing: The Debate Continues
N. K. Gillis et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Design and Anticipated Outcomes of the eMERGE-PGx Project: A Multicenter Pilot for Preemptive Pharmacogenomics in Electronic Health Record Systems
L. J. Rasmussen-Torvik et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
Kelly E. Caudle et al.
CURRENT DRUG METABOLISM (2014)
Clinical Evidence Supporting Pharmacogenomic Biomarker Testing Provided in US Food and Drug Administration Drug Labels
Bo Wang et al.
JAMA INTERNAL MEDICINE (2014)
Doubt About the Feasibility of Preemptive Genotyping
B. C. P. Koch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Response to Doubt About the Feasibility of Preemptive Genotyping
J. C. Denny et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Pharmacogenetic tests: the need for a level playing field
Munir Pirmohamed et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey
E. J. Stanek et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping
J. S. Schildcrout et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
James M. Rae et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Meredith M. Regan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
Glenn N. Levine et al.
CIRCULATION (2011)
Pharmacogenomics: Noninferiority Is Sufficient for Initial Implementation
R. B. Altman
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Pharmacogenetics: From Bench to Byte-An Update of Guidelines
J. J. Swen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Pharmacogenomics and Clopidogrel Irrational Exuberance?
Steven E. Nissen
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study
William G. Newman et al.
PHARMACOGENOMICS (2011)
Assessing the Clinical Utility of Diagnostics Used in Drug Therapy
J. Woodcock
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Establishing Clinical Utility of Pharmacogenetic Tests in the Post-FDAAA Era
B. J. Evans
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Dealing With the Evidence Dilemma in Genomics and Personalized Medicine
M. J. Khoury
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism
Mary V. Relling et al.
LANCET ONCOLOGY (2010)
The Canadian Pharmacogenomics Network for Drug Safety: A Model for Safety Pharmacology
Colin J. D. Ross et al.
THYROID (2010)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2009)
Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine
Felix W. Frueh
PHARMACOGENOMICS (2009)
Clinical relevance of CYP2D6 genetics for tarnoxifen response in breast cancer
Hiltrud Brauch et al.
BREAST CARE (2008)
PERSPECTIVE The Human Genome And Translational Research: How Much Evidence Is Enough?
Janet Woodcock
HEALTH AFFAIRS (2008)
PharmGKB: The Pharmacogenetics Knowledge Base
M Hewett et al.
NUCLEIC ACIDS RESEARCH (2002)
Share Paper
